Stable hydrolysis-resistant synthetic Polyribosylribitolphosphate derivates as 
vaccines against Haemophilus influenzae type b

Seeberger, Peter H.

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Patent

Stable hydrolysis-resistant synthetic Polyribosylribitolphosphate derivates as vaccines against Haemophilus influenzae type b

MPS-Authors

/persons/resource/persons121849

Seeberger, Peter H.
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Seeberger, P. H.(2018). Stable hydrolysis-resistant synthetic Polyribosylribitolphosphate derivates as vaccines against Haemophilus influenzae type b.

Cite as: https://hdl.handle.net/21.11116/0000-0000-740E-F

Abstract

The present invention provides a stable synthetic saccharide of Hib polyribosylribitol- phosphate (PRP) derivative and conjugate thereof. Said saccharide, said conjugate and pharmaceutical compositions thereof are hydrolysis-resistant, long-term stable and useful for the prevention and/or treatment of diseases associated with Haemophilus influenzae, and more specifically of diseases associated with Haemophilus influenzae type b, preferably diseases selected from meningitis, pneumonia, and epiglotitis. They have general formula (I): wherein A is formula (II) or formula (III); B is formula (IV); C is formula (V); D is formula (VI); E is formula (VII); F is formula (VIII) or formula (IX).